Abstract: The present invention provides a dendritic cell-based vaccine by fusing a canine tumor cell and an allogeneic dendritic cell, and a method for preparing the same. The fusion cells expressing canine tumor antigens are generated by fusing canine bone marrow-derived dendritic cells and canine tumor cells. The canine immune system can be induced to produce tumor specific T lymphocytes and natural killer cells when the fusion cells used as a vaccine is injected into a canine body.

Abstract: The present invention is related to a biomarker for diagnosis of canine cancer, wherein the biomarker is KMO (kynureinie 3-monooxygenase) gene, and the canine cancers including CTVT (canine transmissible venereal tumor) and MGT (mammary gland tumor). The expression level of KMO gene in canine malignant tumor tissues is up-regulated as compared with benign tissues. Furthermore, the expression level of KMO gene in malignant tumor tissue is higher than in the non-metastasis tumor tissue. By detection of the expression level of the present invention biomarker in suspecting tissue specimen, malignancy of tumor tissues can be determined correctly and rapidly.

Abstract: The present invention is related to a biomarker for diagnosis of canine cancer, wherein the biomarker is KMO (kynureinie 3-monooxygenase) gene, and the canine cancers including CTVT (canine transmissible venereal tumor) and MGT (mammary gland tumor). The expression level of KMO gene in canine malignant tumor tissues is up-regulated as compared with benign tissues. Furthermore, the expression level of KMO gene in malignant tumor tissue is higher than in the non-metastasis tumor tissue. By detection of the expression level of the present invention biomarker in suspecting tissue specimen, malignancy of tumor tissues can be determined correctly and rapidly.

Abstract: The present invention provides a dendritic cell-based vaccine by fusing a canine tumor cell and an allogeneic dendritic cell, and a method for preparing the same. The fusion cells expressing canine tumor antigens are generated by fusing canine bone marrow-derived dendritic cells and canine tumor cells. The canine immune system can be induced to produce tumor specific T lymphocytes and natural killer cells when the fusion cells used as a vaccine is injected into a canine body.

Abstract: An optical waveguide SPR sensor is adapted for differential measurement. The optical waveguide SPR sensor includes a base, a bottom layer, and at least one set of optical waveguide layers. The set of the optical waveguide layers includes a measuring optical waveguide channel and a reference optical waveguide channel. The measuring optical waveguide channel includes an SPR sensing film layer. The measuring optical waveguide channel and the reference optical waveguide channel are independently configured and substantially parallel one to another. The bottom layer has a refractive index higher than a refractive index of the optical waveguide layer.

Abstract: An optical waveguide SPR sensor is adapted for differential measurement. The optical waveguide SPR sensor includes a base, a bottom layer, and at least one set of optical waveguide layers. The set of the optical waveguide layers includes a measuring optical waveguide channel and a reference optical waveguide channel. The measuring optical waveguide channel includes an SPR sensing film layer. The measuring optical waveguide channel and the reference optical waveguide channel are independently configured and substantially parallel one to another. The bottom layer has a refractive index higher than a refractive index of the optical waveguide layer.

Abstract: Disclosed is a complex immuno-gene medical composition for activating NK cells to enhance a host immune system. The composition includes a plurality of cytokines, including Th1 and Th2 cytokines. Th2 cytokines antagonize TGF-? inhibiting NK cells to disable the inhibition of the immune system. Th1 cytokines activate NK cells in a host to enhance the host's ability to fight against tumor cells. By use of the complex immuno-gene medical composition, removal of tumor cells is expected.

Abstract: Disclosed is a complex immuno-gene medical composition activating NK cells to enhance host immune system. The composition is usage of a combination of a plurality of cytokines, combined usage of the kinds of Th1 and Th2 cytokines. Th2 cytokine antagonizes TGF-? inhibiting NK cells to disable the inhibition of immune system, and Th1 cytokine activates NK cells in host to enhance the ability fighting against tumor cells. By means of the complex immuno-gene medical composition, removal of tumor cells is expectable.

Abstract: The present invention herein relates to a bioactive substance with mammalian B lymphocyte toxicity secreted by canine transmissible venereal tumor (CTVT) and its process. CTVT is the only mammalian tumor in nature that is transmitted through viable tumor cells. Transmission of CTVT between dogs is akin to an allograft. The isolation of bioactive substance secreted by CTVT includes the following steps: (1) store CTVT excised from canine skin in Hank's balanced salt solution (HBSS); (2) physically extract CTVT, tumor infiltrating lymphocytes and peripheral blood lymphocytes; (3) place CTVT in culture medium and physically obtain suspension fluid with B lymphocyte toxicity; (4) drive said suspension solution through protein filters with different pore sizes to obtain bioactive substance.